Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 26Unknown 6Terminated 5Recruiting 3Active not recruiting 2Withdrawn 1Suspended 1Not yet recruiting 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 44Other hematologic neoplasm 23Myeloid 16Dermatologic 12Plasma cell 10Sarcoma 7CNS 7Gynecologic 4Genitourinary 3Breast 3Other 2Head & Neck 1Gastrointestinal 1Classical hematology 1

Conditions

Colorectal Neoplasms 158Pancreatic Neoplasms 148Carcinoma, Hepatocellular 127Colonic Neoplasms 79Stomach Neoplasms 58Rectal Neoplasms 58Liver Neoplasms 47Esophageal Neoplasms 46Breast Neoplasms 40Neoplasms 36Neoplasm Metastasis 35Cholangiocarcinoma 32Lung Neoplasms 23Gastrointestinal Neoplasms 20Ovarian Neoplasms 17Biliary Tract Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Esophageal Squamous Cell Carcinoma 13Uterine Cervical Neoplasms 11Gallbladder Neoplasms 10Adenocarcinoma 10Sarcoma 9Carcinoma, Renal Cell 9Adenocarcinoma Of Esophagus 9Urinary Bladder Neoplasms 8Recurrence 8Bile Duct Neoplasms 8Prostatic Neoplasms 7Gastrointestinal Stromal Tumors 7Colonic Polyps 7

Interventions

Valganciclovir 1Polymerase Chain Reaction 1Biopsy 14-phenylbutyric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hodgkin Disease × Gastrointestinal × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡